Treatment of severe recalcitrant hidradenitis suppurativa with adalimumab.
Hidradenitis suppurativa is a chronic inflammatory skin disease featuring inflammatory nodules, fistulas and discharge of secretions in the intertriginous regions. Without therapy the disease is chronic and progressive. The most effective treatment is the radical wide excision of the affected areas. Systemic antibiotics, immunosuppressants, oral retinoids or antiandrogens have limited beneficial effects. TNF-alpha antagonists may represent a new therapeutic approach for patients suffering from severe hidradenitis suppurativa offering promising positive influence on the disease outcome. In contrast to infliximab and etanercept, there are only few reports describing the use of adalimumab in severe hidradenitis suppurativa. Here we report a case of a patient with severe recalcitrant hidradenitis suppurativa successfully treated with adalimumab.
Harde
Viola
V
Department of Dermatology, Allergy and Venereology, University Clinic Schleswig-Holstein, Campus Kiel, Schittenhelmstrasse 7, Kiel, Germany. vharde@dermatology.uni-kiel.de
Mrowietz
Ulrich
U
D000068879:Adalimumab; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D002908:Chronic Disease; D017497:Hidradenitis Suppurativa / Q000175:diagnosis* / Q000188:drug therapy*; D006801:Humans; D008297:Male; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068879:Adalimumab